Branimir I. Sikic

Branimir I. Sikic

Auto-generated profile, based on publicly available information

Branimir I. Sikic

Clinical and Translational Research Unit, Stanford Cancer Institute, Stanford, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 1990 in Cancer
Verified
Journal Article
Closed access
PDF file
RCRobert W. Carlson
Robert W. Carlson
RDRonald F. Dorfman
Ronald F. Dorfman
BSBranimir I. Sikic
Branimir I. Sikic

17 September 2023 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
MKMargareta Pernar Kovač
Margareta Pernar Kovač
VTVanja Tadic
Vanja Tadic
JKJuran Kralj
Juran Kralj
GDGeorge E. Duran
George E. Duran
ASAlessia Stefanelli
Alessia Stefanelli
Anamaria BrozovicAnamaria Brozovic
Anamaria Brozovic

21 October 1992 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
DLDerick H. M. Lau
Derick H. M. Lau
GDGeorge E. DurÁN
George E. DurÁN
BSBranimir I. Sikic
Branimir I. Sikic
Background : The doxorubicin analogues cyanomorpholino doxorubicin (MRA-CN) and morpholino doxorubicin (MRA) were synthesized in an attempt to avoid the cardiotoxicity and drug resistance of doxorubiricn therapy. MRA-CN forms interstrand DNA cross-links without requiring microsomal metabolic activitation in the presence of reduced nicotinamide adenine dinucleotide phosphate (NADPH) to form a product that alkylates DNA, but MRA requires metabolic activation Alkyalation produces DNA cross-links, which are associated with potentiation of the cytotoxicity of some drugs. Purpose: Our purpose was to study the DNA binding of MRA-CN and MRA with and without metabolic activation in order to better understand the mechanisms for cross linking DNA. Methods: We used ( 3 MRA and ( 3 H) MRA-CN, with the 3 H labeled at C-2 and C-6 of the morpholino ring. MRA (10 n M) was incubated with human liver microsomes with or without NADPH to measure DNA binding. In addition, a filter elution assay was used to determine the nature and extent of drug binding to DNA in the human ovarian carcionma cell line ES-2. We studied the appearence of interstrand crosslinks versus total DNA adducts in pBR322 plasmid DNA incubated with 100 n M MRA-CN in cell free medium and then subjected to denaturation and agarose gel electropohoresis. Results: Regardless of the extracellular concentration of the drug (1– 85% of intracellular MRA-CN was covalently bound to DNA, and the total amount to DNA, and the total amount of drug bound to DNA was proportional to extracellular drug concentration. No covalent binding of MRA to DNA was found in cells exposed to 10 n M MRA alone for 2 hours. In contrast, 10% of the intracellular drug was bound to DNA iof the cells were exposed to MRA preincubated with human liver microsomes and NADPH. The percentages of plasmide containing at least one interstrand cross-links rose from 35% at 15 minutes to 92% at 2 hours. We estimate that eight molecoules of MRA-CN were adducted per molecule of p BR322 DNA (or one drug adduct per 545 base pairs), with a minimum of 12% of the adducts forming interstrand cross links. Conclusions: These result suggest that the carbons at positions 2 and 6 of the morpholino ring of both MRA-CN and the activated metabolite of MRA are retained in the drug-DNA adduct. They also indicate that the formation of interstrand DNA cross links by MRA-CN is preceded by formation of drug adducts to a single strand of DNA. (J Natl Cancer Inst 1587–1592, 1992)

24 March 1998 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
TCTanja Cufer
Tanja Cufer
IVIvan Vrhovec
Ivan Vrhovec
MPMarija Pfeifer
Marija Pfeifer
JSJanez Skrk
Janez Skrk
SBSimona Borstnar
Simona Borstnar
BSBranimir I. Sikic
Branimir I. Sikic


15 July 2016 in Cancer Research
Verified
Journal Article
Closed access
RKRishil J. Kathawala
Rishil J. Kathawala
DMDavid C. Mundy
David C. Mundy
GDGeorge E. Duran
George E. Duran
JVJens-Peter Volkmer
Jens-Peter Volkmer
KKKevin S. Kao
Kevin S. Kao
BSBranimir I. Sikic
Branimir I. Sikic
Macrophage activation by inhibition of CD47 signaling is a new therapeutic approach to cancers. Binding of CD47 to its receptor SIRPα on macrophages initiates a signal cascade that inhibits phagocytosis. Blocking CD47 from interaction with SIRPα by the CD47 antibody Hu5F9-G4 results in phagocytosis of cancer cells, and anticancer activity in xenografts of human cancers. We developed taxane resistant variants from human ovarian carcinoma (OC) cell lines (ES-2, MES-OV and OVCAR-3) by step-wise exposure to paclitaxel (Ptx) and the transport inhibitor valspodar (6x resistance in ES-2/TP, 9x in MES-OV/TP, and 30x in OVCAR-3/TP). These 6 lines were transduced to establish stable luciferase expression for OC xenograft (OCX) imaging. All express CD47 by immunoblotting and flow cytometry, and all express calreticulin (CRT). CRT is a prophagocytic signal that promotes phagocytosis in the presence of CD47 blockade. CRT levels are lower in the Ptx-resistant variants (p<0.01). We are assessing the efficacy of Hu5F9-G4: (1) as a single agent in drug sensitive and resistant OCX; (2) combined with Ptx and carboplatin (Carbo); and (3) combined with cetuximab (Cetux) or trastuzumab (Trastuz) in OCX that express EGFR and/or HER2. We found that EGFR and HER2 are highly expressed in the ovarian cancer TCGA database. All 6 OC lines express EGFR by immunoblotting, and 4 express HER2. Blocking CD47 in vitro induces phagocytosis of parental and drug-resistant OC cell lines by murine macrophages derived from NOD/SCIDgamma (NSG) mice. Hu5F9-G4 has single agent activity in MES-OV OCX, with 89% growth inhibition at 9 weeks (T/C 11%) vs untreated controls (p = 0.03). Ptx alone produced a T/C of 29%, and the combination of Ptx/Hu5F9-G4 3% (p = 0.03 vs Hu5F9-G4; p = 0.0002 vs Ptx). The Carbo experiment was terminated at 5 weeks because of toxicity in the Carbo groups, but at that time point the T/C for Carbo was 59%, Hu5F9-G4 20%, and the antibody combination/carboplatin combination 4% (p<0.005 vs either single agent). In the combined antibody experiment, Hu5F9-G4 T/C was 23%, Cetux 84%, Trastuz 37%, Hu5F9-G4/Cetux 13%, and Hu5F9-G4/Trastuz 12% (p = 0.05 vs Hu5F9-G4 alone). Thus, Hu5F9-G4 has substantial efficacy in MES-OV OCX, and at least additive effects with chemotherapy (Ptx and Carbo) and immunotherapy (Cetux and Trastuz). Experiments with other xenografts are continuing. These results support CD47 as a therapeutic target in OC, and suggest that it may be successfully combined with chemotherapies and other antibodies. Citation Format: Rishil J. Kathawala, David C. Mundy, George E. Duran, Jens-Peter Volkmer, Kevin S. Kao, Yan C. Wang, Aditi Bellary, Irving L. Weissman, Branimir I. Sikic. The anti-CD47 antibody Hu5F9-G4 activates macrophages and inhibits ovarian cancer xenografts, alone and in combination with chemotherapy or immunotherapy. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4001.